Past, Present, and a Glance into the Future of Multiple Myeloma Treatment

Weam Othman Elbezanti; Kishore B. Challagundla; Subash C. Jonnalagadda; Tulin Budak-Alpdogan; Manoj K. Pandey

doi:10.3390/ph16030415

Past, Present, and a Glance into the Future of Multiple Myeloma Treatment

Weam Othman Elbezanti, Kishore B. Challagundla, Subash C. Jonnalagadda, Tulin Budak-Alpdogan, Manoj K. Pandey

Research output: Contribution to journal › Review article › peer-review

11 Scopus citations

Abstract

Multiple myeloma (MM) is a challenging hematological cancer which typically grows in bone marrow. MM accounts for 10% of hematological malignancies and 1.8% of cancers. The recent treatment strategies have significantly improved progression-free survival for MM patients in the last decade; however, a relapse for most MM patients is inevitable. In this review we discuss current treatment, important pathways for proliferation, survival, immune suppression, and resistance that could be targeted for future treatments.

Original language	English (US)
Article number	415
Journal	Pharmaceuticals
Volume	16
Issue number	3
DOIs	https://doi.org/10.3390/ph16030415
State	Published - Mar 2023

Keywords

B-cell malignancy
bone marrow microenvironment
drug resistance
immunotherapies
multiple myeloma
proteasome inhibitors

ASJC Scopus subject areas

Molecular Medicine
Pharmaceutical Science
Drug Discovery

Access to Document

10.3390/ph16030415

Cite this

@article{ba8b70c6aa394eab8e783926f7cac983,

title = "Past, Present, and a Glance into the Future of Multiple Myeloma Treatment",

abstract = "Multiple myeloma (MM) is a challenging hematological cancer which typically grows in bone marrow. MM accounts for 10% of hematological malignancies and 1.8% of cancers. The recent treatment strategies have significantly improved progression-free survival for MM patients in the last decade; however, a relapse for most MM patients is inevitable. In this review we discuss current treatment, important pathways for proliferation, survival, immune suppression, and resistance that could be targeted for future treatments.",

keywords = "B-cell malignancy, bone marrow microenvironment, drug resistance, immunotherapies, multiple myeloma, proteasome inhibitors",

author = "Elbezanti, {Weam Othman} and Challagundla, {Kishore B.} and Jonnalagadda, {Subash C.} and Tulin Budak-Alpdogan and Pandey, {Manoj K.}",

note = "Publisher Copyright: {\textcopyright} 2023 by the authors.",

year = "2023",

month = mar,

doi = "10.3390/ph16030415",

language = "English (US)",

volume = "16",

journal = "Pharmaceuticals",

issn = "1424-8247",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "3",

}

TY - JOUR

T1 - Past, Present, and a Glance into the Future of Multiple Myeloma Treatment

AU - Elbezanti, Weam Othman

AU - Challagundla, Kishore B.

AU - Jonnalagadda, Subash C.

AU - Budak-Alpdogan, Tulin

AU - Pandey, Manoj K.

PY - 2023/3

Y1 - 2023/3

N2 - Multiple myeloma (MM) is a challenging hematological cancer which typically grows in bone marrow. MM accounts for 10% of hematological malignancies and 1.8% of cancers. The recent treatment strategies have significantly improved progression-free survival for MM patients in the last decade; however, a relapse for most MM patients is inevitable. In this review we discuss current treatment, important pathways for proliferation, survival, immune suppression, and resistance that could be targeted for future treatments.

AB - Multiple myeloma (MM) is a challenging hematological cancer which typically grows in bone marrow. MM accounts for 10% of hematological malignancies and 1.8% of cancers. The recent treatment strategies have significantly improved progression-free survival for MM patients in the last decade; however, a relapse for most MM patients is inevitable. In this review we discuss current treatment, important pathways for proliferation, survival, immune suppression, and resistance that could be targeted for future treatments.

KW - B-cell malignancy

KW - bone marrow microenvironment

KW - drug resistance

KW - immunotherapies

KW - multiple myeloma

KW - proteasome inhibitors

UR - http://www.scopus.com/inward/record.url?scp=85152443594&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85152443594&partnerID=8YFLogxK

U2 - 10.3390/ph16030415

DO - 10.3390/ph16030415

M3 - Review article

C2 - 36986514

AN - SCOPUS:85152443594

SN - 1424-8247

VL - 16

JO - Pharmaceuticals

JF - Pharmaceuticals

IS - 3

M1 - 415

ER -

Past, Present, and a Glance into the Future of Multiple Myeloma Treatment

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this